ALS, formally known as amyotrophic lateral sclerosis, is a rare neurological disease involving the nerve cells responsible for controlling voluntary muscle movement, such as chewing, walking, breathing and talking. ALS is progressive, where the condition becomes more severe over time. ALS is also known as Lou Gehrig’s disease.
ALS symptoms can initially be so subtle that they are overlooked. Nevertheless, the symptoms develop into more obvious weakness or atrophy that may cause a physician to suspect ALS.
Early ALS symptoms may include:
The first sign of ALS may appear in the hand or arm as one has trouble with simple tasks such as buttoning a shirt, writing, or turning a key in a lock. Regardless of where the symptoms first appear, muscle weakness and atrophy spread to other body parts as the disease progresses. Individuals may develop problems with moving, swallowing (dysphagia), speaking or forming words (dysarthria), and breathing (dyspnea). Although the sequence of emerging symptoms and the rate of disease progression vary from person to person, individuals will eventually be unable to stand or walk, get in or out of bed on their own, or use their hands and arms.
The cause of ALS is unknown, and scientists do not yet know why ALS strikes some people and not others. However, evidence from scientific studies suggests that genetics and environment play a role in the development of ALS. An essential step toward determining ALS risk factors was made in 1993 when scientists supported by the National Institute of Neurological Disorders and Stroke (NINDS) discovered that mutations in the SOD1 gene were associated with some cases of familial ALS. ALS researchers are also studying the impact of environmental factors. Researchers investigate many possible causes, such as exposure to toxic or infectious agents, viruses, physical trauma, diet, and behavioural and occupational factors.
The Centers for Disease Control and Prevention estimate that 14,000 – 15,000 Americans have ALS.
There are several potential risk factors for ALS, including although the disease can strike at any age, symptoms most commonly develop between the ages of 55 and 75. Men are slightly more likely than women to develop ALS. However, as age increases, the difference between men and women disappears. Race and ethnicity. Caucasians and non-Hispanics are most likely to develop the disease.
Presently, there is no cure for ALS. However, treatments available can help control symptoms, prevent unnecessary complications, and make living with the disease more manageable.
Most with ALS have a lifespan of 3 to 5 years from when the symptoms first appear. However, about 10% of people with ALS survive for ten or more years.
The mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge about ALS. The goals of NINDS research on ALS are to understand the mechanisms involved in the development and progression of the disease, investigate the influence of genetics and other potential risk factors, identify biomarkers, and develop new and more effective treatments.
ALS areas of research:
A universal factor for those living with ALS is the progressive loss of the ability to walk, necessitating a power wheelchair. Quantum Rehab, the global leader in individualized power wheelchair solutions, emphasizes mobility technologies specific to those living with ALS. Quantum powerchairs incorporate power-adjustable seating for user repositioning and comfort; speciality drive controls, including using a single finger or one’s head to operate the powerchair; and a highly adaptable design to meet an individual’s current and future needs.
Quantum powerchairs feature the latest advanced technologies to increase the independence of those living with ALS. iLevel seat elevation technology allows users to operate the powerchair at seated or standing. Bluetooth is also integrated into Quantum’s Q-Logic three electronics, so those with ALS can operate much of their environment with the powerchair drive control. Quantum powerchairs are designed to give those living with ALS optimal medical comfort and maximum independence.
People with ALS often require power mobility assistance very quickly due to the rapidly progressive nature of the disease. In the beginning stages of ALS, a client may need a power chair with high-back support to assist with positioning and performance of mobility-related activities of daily living (MRADLs). A joystick should be used if the individual has adequate hand movement for controlling the powerchair since it provides the most direct control for driving a power base. Giving a client a hand controller with switch jacks is often advised. As the user’s ability changes, switches can be added to operate on/off and mode operations.
As the disease progresses, the individual may find they have a limited time during the day when a joystick can be operated. More advanced electronics, such as a mini-proportional joystick, head array or chin control, may need to be considered to operate the powerchair. The individual will most likely require the use of postural support components and power positioning functions to assist in pressure relief, postural realignment and function. These components may also help with transfers, sitting tolerance and comfort. The power positioning options for consideration include power tilt and recline systems, power-adjustable seat height, power articulating leg rests or a power articulating foot platform. Providing a power base that can accept oxygen and eventually a ventilator is also critical. Optional LED fender lights on the Q6 Edge 2 help clients see and be seen.
Based on the mobility needs of an individual with ALS, they may benefit from a power base with the ability to accept full seating and positioning options, various drive controls, and power positioning. They can accommodate a vent tray and oxygen holder. The Edge 3 and Q6 Edge 2 fit these criteria and are options for a person in the beginning stages of ALS.